Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Early Treatment With Sofosbuvir (SOF) and Ledipasvir (LDV) to Prevent HCV Recurrence After Liver Transplantation (OLT)

NCT02478229 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT02478229
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02478229 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Early Treatment With Sofosbuvir (SOF) and Ledipasvir (LDV) to Prevent HCV Recurrence After Liver Transplantation (OLT)
Lead sponsor
University Health Network, Toronto
Phase
Phase 3
Overall status
Terminated
Start date
June 30, 2015
Completion date
August 31, 2016
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c viral infection